Revenue Recognition and Contractual Adjustments - Narrative (Details)	3 Months Ended
	Mar. 31, 2020 USD ($) segment	Mar. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)
Disaggregation of Revenue [Line Items]
Number of operating segments | segment	2
Increase in Pharma contract assets	$ 200,000
Pharma contract asset, increase (as a percent)	15.00%
Increase in pharma contract liabilities	$ 700,000
Increase in pharma contract liabilities (as a percent)	26.00%
Capitalized contract costs	$ 902,000		$ 931,000
Pharma contract liability, revenue recognized	1,200,000	$ 1,300,000
Amortization of contract commissions	200,000	$ 200,000
Commissions
Disaggregation of Revenue [Line Items]
Increase (decrease) in capitalized contract costs	$ (29,000)
Capitalized contract costs (as a percent)	(3.00%)